Brokers Offer Predictions for Lantheus Holdings, Inc.’s Q2 2024 Earnings (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Stock analysts at B. Riley issued their Q2 2024 earnings per share (EPS) estimates for Lantheus in a research note issued on Wednesday, June 26th. B. Riley analyst Y. Zhi expects that the medical equipment provider will earn $1.67 per share for the quarter. B. Riley has a “Buy” rating and a $99.00 price objective on the stock. The consensus estimate for Lantheus’ current full-year earnings is $6.46 per share. B. Riley also issued estimates for Lantheus’ Q3 2024 earnings at $1.49 EPS, Q4 2024 earnings at $1.52 EPS and FY2024 earnings at $6.18 EPS.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.11. The firm had revenue of $369.98 million during the quarter, compared to the consensus estimate of $349.46 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%.

Other analysts have also recently issued research reports about the company. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Mizuho raised their price objective on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Finally, Truist Financial boosted their target price on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $99.17.

Lantheus Stock Down 0.4 %

NASDAQ LNTH opened at $80.00 on Monday. The stock’s 50 day simple moving average is $77.75 and its 200 day simple moving average is $65.94. Lantheus has a one year low of $50.20 and a one year high of $91.81. The firm has a market cap of $5.54 billion, a PE ratio of 12.21 and a beta of 0.51. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55.

Hedge Funds Weigh In On Lantheus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Shaker Investments LLC OH increased its holdings in Lantheus by 0.7% during the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock worth $1,740,000 after buying an additional 182 shares during the last quarter. NBC Securities Inc. lifted its holdings in Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 191 shares during the last quarter. Retirement Systems of Alabama boosted its stake in Lantheus by 0.3% in the 1st quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider’s stock valued at $5,353,000 after purchasing an additional 226 shares during the period. FinTrust Capital Advisors LLC increased its position in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 232 shares during the period. Finally, UMB Bank n.a. lifted its holdings in shares of Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 247 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Lantheus

In related news, insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the transaction, the insider now owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, insider Daniel Niedzwiecki sold 12,873 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the completion of the transaction, the insider now directly owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now owns 62,898 shares in the company, valued at approximately $4,836,227.22. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,269 shares of company stock valued at $2,557,300. 2.10% of the stock is currently owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.